Patients who have had chemotherapy, hormonal therapy, or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had pelvic radiotherapy prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or immunotherapy within  weeks or radiation therapy within  weeks prior to start of study treatment or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier.
Participants who have had chemotherapy within  weeks or  half-lives (whichever is longer) from the last dose of chemotherapy prior to the first dose of treatment on the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; hydroxyurea is allowed per treating investigator
Use of any other experimental drug or therapy within  days of baseline - patients who have had chemotherapy or radiotherapy within  weeks of entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have received chemotherapy or radiotherapy within  weeks prior to entering the study or has not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy within  days before entering the study or those who have not recovered from AEs to ? Grade  due to agents administered more than  days earlier.
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks of study drug treatment or those who have not recovered from adverse events due to agents administered
Patients who have had molecular targeted therapy (including vemurafenib) or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier.
Patients who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from clinically significant adverse events due to agents administered more than  weeks earlier; the Principal Investigator or treating investigator determine if any abnormal laboratory values or toxicities are due to prior agents administered vs. disease and if they are clinically significant
Patients who have chemotherapy, radiotherapy or oral antifungal agents (ketoconazole, itraconazole, fluconazole) within  weeks prior to entering the study or those who have not recovered (e.g. back to baseline or grade ) from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy, immunotherapy, radiotherapy, or investigational therapy within  days prior to entering the study or those who have not recovered from adverse events due to agents administered more than  days earlier; steroids for control of disease related symptoms are permitted
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy =<  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; treatment with glucocorticoids, hydroxyurea, and tyrosine kinase inhibitors is allowed up to  hour prior to initiation of therapy
Patients who have had chemotherapy, biological therapy or definitive radiation within  weeks of the study enrollment or those who have not recovered from adverse events to =< grade  due to agents administered more than  weeks earlier
Has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Patient has received chemotherapy or radiotherapy within  weeks prior to entering the study or has not recovered sufficiently (PI will judge patient recovery status) from adverse events due to agents administered more than  weeks earlier
Subjects who have received investigational agents, cytotoxic chemotherapy, or radiotherapy within  days prior to entering the study, or who have not recovered from AEs dur to agents administered more than  days earlier.
Participants who have had chemotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who are receiving any concurrent investigational agent with known or suspected activity against multiple myeloma, or those whose adverse events due to agents administered more than  weeks earlier have not recovered to a severity of grade  or grade 
Patients who have received chemotherapy or radiotherapy within  weeks prior to entering the study or has not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have not recovered to =< grade  or tolerable grade  from adverse events due to agents administered >=  days earlier are not eligible
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events (less than or equal to grade  toxicity) due to agents administered more than  weeks earlier
Radiotherapy within  weeks prior to taking the first dose of study drug, or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have not recovered to grade  or less from any adverse events due to agents administered more than  weeks earlier (excluding alopecia)
Patients who have received itraconazole or fluconazole within  weeks prior to registration or those who have not recovered (i.e., back to baseline or grade ) from adverse events (AEs) due to agents administered more than  weeks earlier
Patients who have had chemotherapy or RT within  weeks prior to start of the study agents, or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients must not have received prior chemotherapy or radiation for =<  weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered more than  weeks earlier are excluded
Patients must not have received prior chemotherapy (pentostatin) within  weeks before study enrollment, and those who have not recovered from the adverse events due to agents administered more than  weeks earlier are excluded
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patient has received chemotherapy or radiotherapy within  weeks prior to entering the study or has not recovered from adverse events due to agents administered more than  weeks earlier, with the exception of hydroxyurea
Prior Therapy\r\n* Exposure to chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier\r\n* Systemic steroids that have not been stabilized (>=  days) to the equivalent of =<  mg/day prednisone prior to the start of the study drugs\r\n* No other concurrent investigational agents are allowed
Participants who have had chemotherapy within  weeks, rituximab or obinutuzumab within  weeks, or radioimmunotherapy within  weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than  weeks earlier; subjects actively progressing within that window who have recovered from toxicities of prior therapy are also eligible
Patients who have not recovered (to =< grade  or baseline) from adverse events due to agents administered more than  weeks >=  days earlier are not eligible
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients must not have received prior chemotherapy or radiation for =<  weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered more than  weeks earlier are excluded
Subjects who have had standard cytotoxic chemotherapy or radiotherapy within  weeks prior to entering the study or those whose adverse events due to agents administered more than  weeks earlier have not recovered to =< grade ; this excludes alopecia and hematologic adverse events
Subjects who have received monoclonal antibodies (such as Rituxan) within  week prior to entering the study or those whose adverse events due to agents administered more than  week earlier have not recovered to =< grade ; this excludes hematologic adverse events
Has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Have not recovered from adverse events (must be grade ?) due to agents administered more than  weeks earlier.
Patients who have had chemotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; recovery means resolution to at least grade  toxicity if there was no baseline toxicity or less than or equal to the patients baseline value
JUST PRIOR TO FIRST VACCINATION (WITHIN  DAYS): patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered to baseline from adverse events due to agents administered more than  weeks earlier (washout period)
Has not recovered (i.e., =< grade  or at baseline) from adverse events due to investigational or standard agents administered more than  weeks earlier
Experiencing adverse events due to agents administered more than  days earlier
Patients who have previously received chemotherapy for non-small cell lung cancer, or have received radiotherapy within  weeks prior to entering the study, or who have not recovered from adverse events due to treatment more than  weeks earlier
Patients who have had radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Patients who have not recovered from adverse events due to therapeutic interventions administered more than  weeks earlier
Patients who have had chemotherapy within  weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Receiving MDS treatment except blood transfusion and/or iron chelation within  weeks prior to entering study or no recovery from adverse events due to agents administered more than  weeks earlier.
Patients who have not recovered to grade  or less from any adverse events due to agents administered more than  weeks earlier (excluding alopecia)
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; biological agents, immune modulators, and targeted therapeutic approaches require a -week washout window
Prior chemotherapy, biologic, targeted, or radiotherapy within  weeks prior to entering study or not recovered from grade >=  adverse events (AEs) due to agents administered more than  weeks earlier (except alopecia or neuropathy)
Patients who have had chemotherapy or radiotherapy including complementary and alternative medicine treatments (CAMs) within  weeks prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier, excluding alopecia; patients with treatment related effects, such as peripheral neuropathy, that are grade  or less are eligible
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for radioimmunotherapy) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier (persistent toxicity >= grade )
Patients who have not recovered from adverse events due to agents administered more than  weeks earlier
Chemotherapy (other than hydroxyurea) or radiation within the  weeks prior to planned therapy on this study or ongoing adverse events due to agents administered more than  weeks earlier
Patients who have radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to systemic agents administered more than  weeks earlier
Not recovered from adverse events due to therapy more than  weeks earlier
Patients who have had surgery, chemotherapy or radiotherapy within  weeks prior to entering the study or those who have toxicity that has not recovered to =< grade  from adverse events due to agents administered more than  weeks earlier (with the exception of alopecia); patients may not be receiving any other investigational agents
Patients who have not recovered from adverse events due to agents administered more than  weeks earlier
Chemotherapy within  weeks prior to entering the study, radiotherapy within  weeks prior to entering the study or failure to recover from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have not recovered to =< grade  from adverse events due to agents administered more than  weeks earlier are not eligible
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy, immunotherapy, radiotherapy, or investigational therapy within  days prior to entering the study or those who have not recovered from adverse events due to agents administered more than  days earlier; steroids for control of disease related symptoms are permitted
Chemotherapy within  weeks prior to entering the study, radiotherapy within  weeks prior to entering the study or failure to recover from adverse events to grade  or less due to agents administered more than  weeks earlier
Not recovered from adverse events due to therapy more than  weeks earlier
Patient received chemotherapy or radiotherapy within  weeks prior to entering the study or has not recovered from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Prior therapy\r\n* Exposure to chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier\r\n* Systemic steroids that have not been stabilized (>=  days) to the equivalent of =<  mg/day prednisone prior to the start of the study drugs\r\n* No other concurrent investigational agents are allowed
Participants who have had any major surgery =<  days prior to the planned initiation of study therapy, or those who have not recovered from adverse events due to agents/surgery administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy within  days prior to entering the study (with the exception of trastuzumab) or those who have not recovered from adverse events to =< grade  due to agents administered more than  weeks earlier
Participants who have had chemotherapy within  weeks prior to entering the study, or lack of recovery from adverse events to grade  or less due to systemic agents administered more than  weeks earlier; patients can be eligible if  weeks have passed since receipt of erlotinib
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier.
Patients who have had chemotherapy for the treatment of metastatic breast cancer are not eligible. Patients who have had radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier are not eligible.
Participants who have not recovered from adverse events due to systemic agents administered more than  weeks earlier, as determined by the treating physician
Participants who have had immunotherapy, chemotherapy, experimental therapy or radiotherapy within  weeks before first day of study drug dosing or those who have not recovered to grade  or baseline from adverse events due to agents administered more than  weeks earlier
Participants who have had chemotherapy or radiotherapy (including investigational agents) within  weeks prior to entering the study or those who have not recovered adequately from adverse events due to agents administered more than  weeks earlier (excluding alopecia); washout from trastuzumab is not required
Patient has had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who, at the discretion of the treating physician, have not recovered from adverse events due to agents administered earlier
Participants who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier.
Patients who have had chemotherapy, immunotherapy, or investigational anti-cancer therapy within  weeks of starting study drug, or radiotherapy within  days of starting study drug, or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had major surgery, chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events (CTCAE v. grade  or greater, excluding alopecia) due to agents administered more than  weeks earlier
Patients who have had palliative chemotherapy prior to entering the study <  months from enrollment or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy =<  days (=<  weeks for monoclonal antibodies) prior to first administration of study treatment or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy, biologic, targeted, or radiotherapy within  weeks prior to entering the study or those who have not recovered from grade  and above adverse events due to agents administered more than  weeks earlier (with the exception of alopecia or neuropathy)
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse event from agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Myelosuppressive therapy for myeloma =<  days prior to registration or those who have not recovered from acute reversible adverse events due to agents administered >  days earlier
Patients must not have received systemic therapy or radiotherapy within the preceding  weeks; patients must have recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy, immunotherapy, or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events (=< grade  or patients baseline) due to agents administered more than  weeks earlier are not eligible
Subjects who have had radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents or therapies administered for treatment of prostate cancer more than  weeks earlier- (except urinary, rectal, and sexual side effects related to prostatectomy or radiotherapy are permitted)
Patients who are:\r\n* Receiving or received treatment with an investigational agent within  weeks prior to entering the study OR\r\n* Have not recovered from adverse events due to agents administered more than  weeks earlier as determined by the treating physician
Patients who have had other chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier are not eligible.
Patients who have had antifungal agents (itraconazole, fluconazole) within  weeks prior to treatment start or those who have not recovered from adverse events (AEs) due to these agents administered more than  weeks earlier
Participants who have had radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or immunotherapy within  weeks of starting study drug, or radiotherapy within  days of starting study drug, or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Subjects who have not recovered from adverse events due to pharmaceutical or diagnostic agents administered more than  weeks earlier.
Subjects who have not recovered from adverse events due to pharmaceutical or diagnostic agents administered more than  weeks earlier.
